Skip to main content
. 2019 Jul 1;2019:7561879. doi: 10.1155/2019/7561879

Figure 1.

Figure 1

Inhibition of NAT10 using remodelin increases the chemosensitivity of HCC cell lines to doxorubicin. (a–d) CCK-8 assay of cell viability. (e–h) Representative images and quantification of EdU incorporation assay of cell growth and DNA synthesis. P < 0.05, doxorubicin vs. control cells; #P < 0.05, doxorubicin+remodelin vs. remodelin.